NEW JERSEY and HANGZHOU, CHINA, April 13, 2021 -- Adlai Nortye, a global clinical-stage biopharmaceutical company focused on developing innovative oncology drugs, today announced that it has presented an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 which takes place on and .
Key findings of the e-poster are described below:
Session Category: Targeting the Tumor Microenvironment in Drug Development
Title: AN3025: an immune-stimulatory anti-human TNFR2 (Tumor Necrosis Factor Receptor-2) antibody with strong anti-tumor activity
Authors: Yonglin Chen, Manxue Jia, Yanhui Zhao, Eric Chan, Meng Zhang, Emma Chen, Yi Zhang, Sherry Xu
Abstract #: 1451, click here to view the e-poster
AN3025 was generated through rabbit immunization followed by phage display, then humanized by CDRs grafting. The binding affinity and specificity were studied by ELISA and FACS. The ability of AN3025 to mitigate TNF/TNFR2 signaling pathway was characterized using TNFR2 overexpressing Jurkat cell line in vitro. The in vivo anti-tumor activity was evaluated in TNFR2 humanized mouse model bearing MC38 tumor. Our early pre-clinical data demonstrate that AN3025 binds human TNFR2 with high affinity and blocks its interaction with TNFα, which enhances IFNγ production in Treg/Teff co-culture assay and significantly inhibits MC38 tumor growth as a monotherapy in the hTNFR2 mouse model.
“The anti-hTNFR2 antibody program (AN3025) has demonstrated great potentials in controlling tumors pre-clinically,” said Dr. Nanhai He, Head of Drug Discovery of Adlai Nortye. “We’ll continue to push this exciting program forward and are looking forward to its clinical development soon.”
AN3025 is a novel humanized IgG1 (variant) anti-hTNFR2 antibody that is currently under pre-clinical development. This antibody binds to the extracellular domain of human TNFR2 with sub-nanomolar affinity and occludes its ligand TNFa from accessing TNFR2. Since TNFR2 is highly expressed on a subset of immunosuppressive cells, including regulatory T cells (Tregs) and MDSCs, within tumor microenvironment, AN3025 is expected to amplify the antitumor immune response to aid in immunotherapy.
About Adlai Nortye
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, the Company has built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. Currently, three of them are being investigated in clinical trials, including the FDA Fast Track-designated Buparlisib (AN2025) in a global phase III clinical trial; the FDA Fast Track-designated intravenously-administered oncolytic virus Pelareorep (AN1004) to have completed a phase II clinical trial; and an oral EP4 antagonist (AN0025) is in early-stage clinical development in multiple tumor types in combination with other treatment options including chemo-radiation and anti‑PD‑1/anti‑PD‑L1 therapies.
The Company has assembled a world-class management team, built its unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. Adlai Nortye is committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. The ultimate goal of the Company is to transform cancer into manageable conditions. For more information, please visit: www.adlainortye.com.